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ABSTRACT	  
	  
Aminoglycosides	  have	  proven	  very	  useful	  in	  the	  treatment	  of	  infections;	  lately	  their	  
effectiveness	  has	  been	  greatly	  reduced	  due	  to	  increasing	  resistance.	  Among	  many	  known	  
mechanisms	  of	  resistance	  to	  aminoglycosides,	  enzymatic	  modification	  is	  the	  most	  prevailing.	  
More	  than	  14	  aminoglycoside	  -­‐N3-­‐acetyltransferases-­‐	  a	  class	  of	  aminoglycoside	  modifying	  
enzymes,	  are	  known	  today.	  	  This	  study	  focuses	  on	  a	  pair	  of	  acetyl	  transferases:	  The	  
aminoglycoside-­‐N3-­‐	  acetyltransferase	  IIIb	  (AAC-­‐IIIb)	  and	  the	  aminoglycoside-­‐N3-­‐	  
acetyltransferase	  IIa	  (AAC-­‐IIa).	  	  AAC-­‐IIa	  and	  AAC-­‐IIIb	  are	  very	  similar	  in	  their	  amino	  acid	  
sequence	  and	  structure	  –	  yet	  they	  have	  a	  strong	  difference	  in	  their	  substrate	  selectivity,	  kinetic	  
and	  thermodynamic	  properties.	  This	  work	  represents	  a	  comparative	  study	  of	  these	  two	  
enzymes	  in	  an	  effort	  to	  determine	  thermodynamic	  basis	  of	  the	  differential	  substrate	  profiles	  of	  
AAC-­‐IIa	  to	  AAC-­‐IIIb.
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 Chapter	  1:	  Introduction	  
	  




An	  aminoglycoside	  is	  a	  molecule	  composed	  of	  amino	  modified	  sugars.	  
Aminoglycoside	  antibiotics	  are	  traditional	  therapeutic	  agents	  against	  gram	  negative	  
bacterial	  strains	  and	  a	  few	  anaerobic	  bacilli	  [1].	  Streptomycin	  was	  the	  first	  of	  this	  kind	  of	  
antibiotics	  to	  be	  used	  to	  treat	  tuberculosis	  after	  its	  discovery	  in	  1941.	  	  Aminoglycoside	  
antibiotics	  do	  have	  potent	  side	  effects	  such	  as	  nausea,	  fatigue,	  anaphylactic	  shock,	  
ototoxicity	  and	  nephrotoxicity,	  justifying	  for	  their	  use	  to	  be	  carefully	  monitored	  [2,	  3].	  In	  
the	  United	  States	  the	  U.S.	  Food	  and	  Drug	  Administration	  has	  approved	  streptomycin,	  
neomycin,	  gentamycin,	  tobramycin,	  amikacin	  and	  paramomycin	  for	  clinical	  use	  [4].	  In	  
combination	  with	  other	  anti-­‐bacterials,	  aminoglycoside	  antibiotics	  are	  also	  used	  to	  treat	  
gram-­‐positive	  infections.	  They	  have	  also	  been	  shown	  to	  be	  effective	  to	  treat	  protozoan	  
and	  mycobacterial	  infections	  as	  well	  as	  some	  genetic	  diseases,	  cystic	  fibrosis	  and	  
inhibition	  of	  the	  HIV	  virus	  reproduction	  [5].	  	  The	  extensive	  use	  of	  these	  antibiotics	  is	  due	  
to	  their	  diverse	  chemical	  structures,	  origins	  and	  availability	  [6].	  Aminoglycoside	  
antibiotics,	  just	  like	  other	  classes	  of	  antibiotics,	  are	  a	  group	  of	  antimicrobial	  compounds	  
currently	  experiencing	  reduced	  efficiency	  in	  fighting	  bacterial	  infections,	  due	  to	  growing	  
bacterial	  resistance	  against	  them.	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ii.	  Nomenclature	  and	  Classification:	  
	  
Most	  aminoglycoside	  antibiotics	  originate	  from	  either	  bacteria	  or	  fungi,	  unless	  
they	  are	  synthetic.	  The	  general	  nomenclature	  of	  antibiotics	  are	  such	  that	  those	  derived	  
from	  the	  bacteria	  of	  the	  Streptomyces	  genus	  are	  named	  with	  a	  suffix	  of	  ‘mycin’	  and	  the	  
ones	  from	  the	  fungus	  Micromonospora	  are	  named	  with	  a	  suffix	  ‘micin’	  [7].	  	  Penicillin	  is	  
derived	  from	  Penicillium	  fungi	  whereas	  Streptomycin	  is	  derived	  from	  the	  
actinobacterium	  Streptomyces	  griseus	  [8].	  However,	  the	  façade	  of	  the	  suffixes	  does	  not	  
suggest	  common	  mechanism	  of	  action.	  For	  instance,	  vancomycin,	  a	  glycopeptide	  
antibiotic	  binds	  to	  the	  amino	  acids	  within	  the	  cell	  wall	  thereby	  inhibiting	  cell	  wall	  
synthesis	  while	  paromomycin	  binds	  to	  the	  16S	  ribosomal	  RNA	  and	  inhibits	  protein	  
synthesis.	  In	  contrast,	  erythromycin,	  a	  macrolide	  inhibits	  protein	  synthesis	  by	  preventing	  
the	  activity	  of	  the	  peptidyltransferase	  that	  forms	  peptide	  bonds	  between	  adjacent	  
amino	  acids	  during	  protein	  synthesis	  [9-­‐11].	  	  
	  
The	  majority	  of	  aminoglycoside	  antibiotics	  can	  be	  classified	  into	  two	  major	  
categories:	  the	  neomycin	  family	  and	  the	  kanamycin	  family.	  They	  have	  a	  common	  2-­‐
deoxystreptamine	  (2-­‐DOS)	  ring	  that	  is	  linked	  by	  glycosidic	  bonds	  to	  the	  amino	  sugars	  [3]	  
,as	  shown	  in	  Figure	  1.	  	  As	  noted	  in	  the	  kanamycin	  structure,	  rings	  A,	  B,	  and	  C	  are	  
referred	  to	  as	  the	  primed,	  unprimed	  and	  double	  primed	  rings,	  respectively.	  The	  
kanamycin	  family	  of	  aminoglycosides	  have	  a	  4,6-­‐disubstituted	  central	  deoxystreptamine	  
ring	  while	  the	  ones	  belonging	  to	  the	  neomycin	  family	  have	  a	  4,5-­‐disubstituted	  central	  
deoxystreptamine	  ring	  [12].	  	  Addition	  of	  methyl,	  amino	  and	  hydroxyl	  groups	  and	  of	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sugar	  rings,	  are	  a	  few	  of	  the	  many	  modifications	  found	  to	  occur	  on	  the	  chemical	  






Figure	  1:	  Structures	  of	  few	  aminoglycoside	  antibiotics	  -­‐	  (L)	  Kanamycin	  family	  (R)	  Neomycin	  
family.	  Figure	  reprinted	  with	  permission	  from	  Ozen,	  C.,	  et	  al.,	  Detection	  of	  specific	  solvent	  
rearrangement	  regions	  of	  an	  enzyme:	  NMR	  and	  ITC	  studies	  with	  aminoglycoside	  
phosphotransferase	  (3')-­‐IIIa.	  Biochemistry,	  2008.	  47(1):	  p.	  40-­‐9.	  	  Copyright	  ©	  2008,	  American	  




iii.	  Mode	  of	  Action:	  
	  
Early	  studies	  to	  understand	  the	  mechanism	  of	  aminoglycosides	  antibacterial	  action	  
showed	  that	  they	  caused	  miscoding	  during	  the	  protein	  synthesis,	  leading	  to	  low	  cell	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sustainability	  and	  improper	  cell	  wall	  formation,	  and	  eventually,	  cell	  death	  [13].	  Due	  to	  their	  
protonated	  amine	  moieties	  they	  have	  a	  high	  binding	  affinity	  to	  the	  RNAs,	  especially	  to	  the	  
prokaryotic	  rRNA	  that	  is	  10	  fold	  higher	  as	  compared	  to	  the	  eukaryotic	  rRNA	  [14,	  15].	  They	  
are	  known	  to	  bind	  the	  tRNA,	  the	  Rev	  response	  element	  (RRE)	  for	  transcriptional	  activation	  
region	  in	  human	  immunodeficiency	  virus	  (HIV),	  the	  hammerhead	  ribozyme,	  group	  I	  self-­‐
splicing	  introns	  and	  the	  ribozyme	  from	  the	  hepatitis	  delta	  virus	  [16].	  	  Other	  studies	  
discovered	  that	  the	  aminoglycosides	  bind	  to	  the	  amino-­‐acyl-­‐tRNA	  decoding	  site	  (A-­‐site)	  on	  
the	  16S	  RNA	  subunit	  of	  the	  ribosome	  [15].	  Crystal	  structure	  shows	  that	  when	  the	  free	  30S	  
ribosomal	  subunit	  is	  unbound	  there	  is	  a	  loop	  on	  the	  A-­‐site	  in	  which	  two	  adenines	  are	  folded	  
back	  inside	  the	  helix.	  At	  the	  A-­‐site,	  the	  matching	  of	  correct	  anticodon	  to	  the	  codon	  of	  the	  
mRNA	  is	  done	  during	  translation.	  Upon	  accurate	  matching,	  these	  two	  adenines	  are	  
unfolded	  from	  the	  helix	  and	  translation	  occurs	  [17-­‐19].	  	  One	  crystallography	  study	  has	  
shown	  that	  upon	  binding	  of	  the	  aminoglycoside	  paromomycin	  to	  the	  30S	  ribosomal	  unit,	  
the	  primed	  ring	  of	  the	  aminoglycoside	  was	  inserted	  inside	  the	  helix,	  forcing	  the	  two	  
adenines	  out	  of	  the	  helix.	  The	  central	  unprimed	  ring	  also	  shows	  interaction	  with	  many	  
conserved	  base	  pairs	  of	  the	  A-­‐site	  [16].	  	  Hence,	  the	  primed	  and	  unprimed	  rings	  of	  the	  
aminoglycosides	  hinder	  the	  process	  of	  translation	  by	  binding	  to	  the	  conserved	  regions	  of	  
the	  16S	  rRNA,	  causing	  mistranslations	  and	  premature	  stops	  in	  protein	  synthesis,	  resulting	  in	  
cell	  death.	  Later,	  studies	  from	  our	  research	  group	  demonstrated	  that	  the	  primed	  and	  
unprimed	  rings	  of	  aminoglycosides	  adopt	  a	  similar	  conformation	  when	  bound	  to	  
aminoglycoside	  modifying	  enzymes	  and	  make	  the	  most	  significant	  interactions	  with	  these	  
enzymes	  [20].	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iv.	  Antibiotic	  Resistance:	  
	  
Antibiotics	  are	  a	  wonderful	  invention	  for	  curing	  infections	  caused	  by	  bacteria.	  
Unfortunately	  bacteria	  are	  adept	  at	  developing	  resistance	  against	  them.	  	  Upon	  over	  
exposure	  to	  the	  same	  antibiotics,	  bacterial	  population	  becomes	  available	  to	  develop	  the	  
ability	  to	  modify	  these	  drugs	  to	  alleviate	  their	  toxic	  effect.	  Examples	  of	  such	  modification	  of	  
antibiotics	  include	  a	  change	  in	  the	  structure	  of	  the	  drug,	  inactivating	  or	  neutralizing	  its	  
effect	  [7].	  Bacteria	  are	  also	  able	  to	  transfer	  genes	  coding	  for	  antibiotic	  resistance,	  rapidly	  
spreading	  resistance	  to	  a	  particular	  antibiotic	  [6].	  This	  issue	  is	  amplified	  when	  the	  antibiotics	  
are	  used	  to	  treat	  infections	  against	  which	  they	  are	  not	  effective	  or	  as	  preventative	  measure,	  
instead	  of	  treatment.	  Resistance	  to	  antibiotics	  poses	  a	  serious	  problem,	  as	  an	  increasing	  
number	  of	  infections	  can	  no	  longer	  be	  treated	  with	  existing	  medications.
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II.	  Aminoglycoside	  Modifying	  Enzymes:	  
	  
i.	  Classification,	  peculiarities	  and	  significance:	  
	  
Aminoglycosides	  are	  a	  broad	  group	  of	  antibiotics	  that	  are	  produced	  by	  actinomycetes	  as	  
a	  defense	  mechanism	  against	  other	  bacteria	  [1,	  12].	  	  In	  order	  to	  overcome	  the	  effects	  of	  
antibiotics,	  bacteria	  also	  produce	  enzymes	  that	  modify	  aminoglycosides	  to	  mediate	  
antibiotic	  resistance	  and	  render	  them	  harmless	  [3].	  	  To	  date,	  from	  both	  gram-­‐positive	  and	  
gram-­‐negative	  bacteria,	  there	  are	  more	  than	  50	  known	  enzymes	  that	  modify	  
aminoglycoside.	  These	  enzymes	  are	  known	  as	  the	  aminoglycoside	  modifying	  enzymes	  
(AGMEs)	  [21].	  AGMEs	  are	  divided	  in	  classes	  based	  on	  the	  chemical	  group	  they	  transform	  
[22].	  The	  three	  major	  classes	  of	  AGMEs	  are;	  the	  acetyltransferases	  (AACs)	  -­‐catalyze	  the	  
acetyl	  CoA-­‐dependent	  acetlylation	  of	  an	  amino	  group,	  the	  nucleotidyltransferases	  (ANTs)	  -­‐	  
catalyze	  ATP-­‐dependent	  adenylation	  of	  hydroxyl	  groups	  and	  the	  phosphotransferases	  
(APHs)	  -­‐	  catalyze	  ATP-­‐dependent	  phosphorylation	  of	  a	  hydroxyl	  group.	  AGMEs	  are	  further	  
characterized	  by	  the	  location	  of	  the	  modification	  that	  they	  enable.	  For	  example	  
aminoglycoside	  phosphotransferase	  3’	  type	  IIIa	  (APH	  (3’)-­‐IIIa)	  phosphorylates	  the	  hydroxyl	  
attached	  to	  the	  C-­‐3	  on	  the	  primed	  ring	  of	  the	  aminoglycoside	  antibiotic[23].	  	  Various	  
modification	  sites	  of	  AGMEs	  are	  shown	  on	  a	  Kanamycin	  family	  aminoglycoside	  antibiotic	  in	  
Figure	  2.	  Because	  different	  AGME	  may	  catalyze	  	  	  similar	  chemical	  modifications,	  these	  
AGME	  are	  further	  characterized	  by	  discovery	  and	  resistance	  profile	  [24].	  	  Within	  each	  family	  
of	  AGME	  transferases,	  substrate	  promiscuity	  varies,	  i.e.	  many	  enzymes	  are	  able	  to	  modify	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several	  structurally	  diverse	  aminoglycoside	  antibiotics	  and	  are	  not	  specific	  to	  just	  a	  single	  
aminoglycoside.	  	  	  
Modifications	  to	  aminoglycosides	  by	  catalytic	  action	  of	  AGMEs	  reduces	  the	  binding	  
affinity	  of	  aminoglycosides	  for	  the	  A	  site	  of	  the	  30S	  RNA	  subunit	  by	  creating	  unfavorable	  
electrostatic	  interactions	  and	  steric	  hindrance.	  	  To	  simplify,	  when	  a	  negatively	  charged	  
phosphate	  group	  is	  added,	  it	  changes	  the	  attraction	  of	  the	  aminoglycoside	  to	  the	  negatively	  
charged	  A-­‐site	  [16].	  Chemical	  modifications	  at	  different	  sites	  on	  aminoglycosides	  decrease	  
their	  binding	  affinity	  for	  the	  A-­‐site	  to	  varying	  degrees.	  Further,	  bacterial	  strains	  are	  likely	  to	  
produce	  several	  aminoglycoside	  modifying	  enzymes	  [25].	  The	  study	  of	  these	  enzymes	  is	  
thus	  not	  only	  relevant	  to	  the	  treatment	  of	  infections	  but	  also	  can	  be	  of	  immense	  help	  for	  
future	  drug	  design	  and	  development.	  Apart	  from	  clinical	  interest,	  analysis	  of	  AGME	  and	  its	  
substrates	  gives	  insights	  into	  the	  understanding	  of	  protein-­‐ligand	  interactions,	  as	  many	  of	  
these	  enzymes	  interact	  with	  various	  aminoglycoside	  antibiotics.	  This	  can	  also	  help	  to	  explain	  
“dynamics”,	  which	  measures	  the	  nature	  and	  degree	  of	  fluctuations	  in	  the	  protein	  structure	  
in	  presence	  and	  absence	  of	  ligands.	  Understanding	  molecular	  basis	  of	  “promiscuity”	  to	  
determine	  reasons	  for	  interaction	  with	  a	  wide	  set	  of	  substrates	  for	  a	  protein	  are	  also	  
studied	  using	  this	  family	  of	  enzymes.	  	  
The	  AGMEs	  are	  often	  characterized	  in	  terms	  of	  promiscuity.	  If	  the	  AGME	  can	  bind	  a	  
large	  number	  of	  substrates,	  it	  is	  considered	  promiscuous	  while	  the	  ones	  that	  can	  bind	  to	  
only	  few	  substrates	  have	  low	  promiscuity.	  In	  this	  work,	  we	  define	  an	  AGME	  to	  be	  
promiscuous	  if	  it	  can	  bind	  to	  two	  or	  more	  classes	  of	  aminoglycosides.	  For	  instance,	  the	  
aminoglycoside	  phosphotransferase-­‐IIIa,	  APH	  (3’)-­‐IIIa,	  can	  modify	  over	  15	  aminoglycosides	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from	  the	  kanamycin	  and	  neomycin	  families.	  APH	  (3’)-­‐IIIa	  is	  qualified	  as	  highly	  promiscuous	  
in	  this	  work.	  While	  an	  acetyl	  transferase,	  AAC	  (3)-­‐IIa	  can	  only	  modify	  several	  members	  of	  
kanamycins,	  it	  is	  unable	  to	  modify	  neomycins	  at	  an	  appreciable	  rate	  and	  it	  is	  qualified	  as	  
having	  a	  moderately	  low	  promiscuity.	  On	  the	  other	  hand,	  the	  aminoglycoside	  
acetyltransferase	  (3)-­‐VIa	  only	  modifies	  3	  members	  of	  the	  kanamycins,	  which	  represents	  a	  
limited	  substrate	  profile.	  Sequence	  comparison	  of	  AGMEs	  showed	  that	  neither	  promiscuity	  
nor	  substrate	  overlap	  could	  be	  deduced	  from	  amino	  acid	  sequence	  analysis.	  For	  example,	  
AGMEs	  with	  less	  than	  10%	  sequence	  similarity	  can	  have	  a	  large	  substrate	  overlap.	  
Conversely,	  enzymes	  with	  sequence	  similarity	  of	  50-­‐60%	  may	  have	  non-­‐overlapping	  
substrate	  profiles.	  The	  same	  conclusion	  can	  be	  made	  regarding	  their	  substrate	  promiscuity.	  
[21].	  	  	  
To	  date,	  several	  AGMEs	  have	  been	  studied	  using	  kinetic,	  biochemical	  and	  biophysical	  
techniques	  [26,	  27].	  Several	  crystal	  structures	  of	  AGMEs	  are	  also	  available,	  with	  or	  without	  
bound	  substrates	  [27-­‐31].	  However,	  the	  molecular	  basis	  for	  the	  discrepancy	  in	  substrate	  
specificity	  between	  these	  enzymes	  remains	  unidentified.	  
	  
	  
Figure	  2:	  Various	  AGME	  modification	  sites	  shown	  on	  aminoglycoside	  antibiotic	  Kanamycin	  B
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Chapter	  2:	  The	  Two	  Acetyl	  Transferases	  -­‐	  So	  Alike	  Yet	  So	  Different!	  
	  




	   Inactivation	  by	  AGMEs	  is	  one	  of	  the	  most	  prevalent	  mechanisms	  used	  by	  bacteria	  to	  
create	  resistance	  to	  the	  aminoglycoside	  antibiotics.	  	  One	  such	  class	  of	  AGMEs	  is	  the	  
aminoglycoside	  N-­‐acetyltransferases	  (AACs).	  AACs	  belong	  to	  the	  GCN5-­‐related	  N-­‐
acetyltransferase	  (GNAT)	  superfamily	  that	  consists	  of	  over	  10,000	  proteins	  [32].	  	  The	  GNAT	  
enzymes	  use	  acetyl	  coenzyme	  A	  as	  a	  donor	  substrate	  to	  catalyze	  the	  acetylation	  of	  the	  –
NH2	  groups	  in	  the	  acceptor	  molecule.	  Crystal	  structures	  of	  several	  acetyltransferases	  have	  
been	  resolved	  along	  with	  extensive	  study	  of	  its	  mechanical	  and	  structural	  aspects	  [33-­‐35].	  
Depending	  on	  the	  position	  of	  the	  –NH2	  modified	  by	  the	  AACs	  by	  acetylation,	  these	  enzymes	  
are	  further	  classified	  as	  AAC	  (1),	  AAC	  (3),	  AAC	  (2’)	  and	  AAC	  (6’)	  [25].	  
	  
	   This	  work	  focuses	  on	  two	  AAC	  (3)	  enzymes	  that	  catalyze	  the	  transfer	  of	  an	  acetyl	  
coenzyme	  A	  (AcCoA)	  to	  the	  amine	  groups	  at	  the	  C3	  position	  of	  the	  aminoglycosides.	  	  This	  





Figure	  3:	  Acetylation	  of	  the	  aminoglycoside	  Tobramycin	  via	  AAC	  (3).	  
	  
The	  substrate	  profile	  and	  promiscuity	  of	  various	  AAC	  (3)	  enzymes	  vary.	  This	  work	  
focuses	  on	  a	  low	  promiscuity	  protein,	  the	  aminoglycoside	  N3	  acetyltransferase	  IIa	  (AAC-­‐IIa)	  
and	  compares	  it	  to	  the	  aminoglycoside	  N3	  acetyl	  transferase	  IIIb	  (AAC-­‐IIIb),	  APH	  (3’)-­‐IIIa	  
and	  to	  an	  aminoglycoside	  nucleotidyltransferase,	  (4’)	  (ANT),	  previously	  characterized	  by	  
our	  research	  group.	  	  The	  substrates	  used	  throughout	  this	  study	  are	  the	  aminoglycoside	  















Figure	  4:	  Structures	  of	  substrates	  used	  in	  this	  study	  (Top)	  aminoglycoside	  antibiotic	  Tobramycin	  


















ii.The	  Aminoglycoside	  N3	  Acetyltransferase	  IIa:	  
	  
	   	   The	  aminoglycoside	  N3	  acetyltransferase	  IIa	  (AAC-­‐IIa)	  is	  a	  prokaryotic	  protein.	  It	  is	  30.5-­‐
kDa	  constituting	  of	  286	  amino	  acids	  and	  is	  produced	  by	  gram-­‐negative	  bacteria.	  AAC-­‐IIa	  
comprises	  about	  85	  percent	  of	  the	  clinical	  isolates	  that	  possess	  an	  AAC	  (3)-­‐II	  type	  gene.	  AAC-­‐IIa	  
catalyzes	  the	  AcCoA-­‐dependent	  acetylation	  of	  the	  amine	  group	  at	  the	  C3	  position	  on	  an	  
aminoglycoside	  antibiotic.	  	  AAC-­‐IIa	  is	  a	  weakly	  promiscuous	  enzyme:	  it	  modifies	  the	  kanamycin	  
class	  of	  aminoglycosides	  and	  has	  slow	  turnover	  rates	  when	  the	  neomycin	  class	  are	  substrates	  
[36].	  Thus	  far,	  this	  protein	  is	  the	  only	  AGME	  that	  has	  been	  characterized	  with	  least	  level	  of	  
substrate	  promiscuity.	  No	  crystal	  structure	  is	  available	  for	  this	  enzyme,	  however	  a	  homology-­‐
derived	  model	  has	  been	  determined	  [36].	  The	  large	  number	  of	  negatively	  charged	  side	  chains	  in	  
the	  active	  site	  of	  the	  homology-­‐derived	  model	  is	  consistent	  with	  other	  AGMEs,	  representing	  a	  
large	  surface	  for	  the	  binding	  of	  positively	  charged	  aminoglycosides.	  	  	  
	   	   When	  comparing	  AAC-­‐IIa,	  to	  AAC-­‐IIIb	  and	  APH	  (3)-­‐IIIa	  of	  similar	  molecular	  weight,	  AAC-­‐
IIa	  has	  about	  70	  percent	  sequence	  similarity	  with	  AAC-­‐IIIb	  (Figure	  3)	  and	  shares	  no	  homology	  
(<5	  percent)	  with	  APH	  (3’)-­‐IIIa.	  However,	  AAC-­‐IIa,	  like	  APH	  (3’)-­‐IIIa,	  possess	  short	  amino	  acid	  
segments	  considered	  to	  be	  disordered	  because	  they	  have	  been	  shown	  to	  be	  relatively	  flexible	  
in	  an	  apo	  form	  by	  Nuclear	  Magnetic	  Resonance	  (NMR).	  NMR	  data	  acquired	  with	  this	  30-­‐kDa	  
enzyme	  shows	  that,	  just	  like	  APH	  (3’)-­‐IIIa,	  the	  apo-­‐enzyme	  is	  a	  highly	  dynamic	  protein	  displaying	  
a	  significantly	  overlapped	  spectrum.	  In	  both	  cases,	  binding	  of	  aminoglycosides	  dramatically	  
alter	  the	  NMR	  spectra,	  causing	  it	  to	  become	  well	  resolved,	  indicative	  of	  a	  well-­‐defined	  structure	  
of	  the	  protein	  in	  solution	  [21,	  36,	  37].	  This	  does	  not	  seem	  to	  be	  the	  case	  for	  AAC-­‐IIIb;	  it	  is	  
structured	  in	  both	  its	  apo	  form	  and	  in	  binary	  complexes	  with	  its	  substrates.	  Yet,	  AAC-­‐IIIb	  is	  
	  13	  
much	  more	  promiscuous	  than	  AAC-­‐IIa	  [21,	  36,	  38,	  39].	  These	  observations	  suggest	  that	  
enzymes	  that	  have	  high	  promiscuity	  are	  not	  necessarily	  more	  dynamic	  in	  structure	  than	  those	  
with	  a	  lower	  promiscuity.	  
	  
	  
	   	  
	  
	  
Figure	  5:	  Sequence	  alignment	  of	  the	  two-­‐acetyl	  transferases:	  AAC-­‐IIa	  and	  AAC-­‐IIIb.	  “*”	  Indicates	  
conserved	  residues,	  	  “:”	  is	  an	  indication	  of	  conservation	  between	  groups	  of	  similar	  properties	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Since	  the	  AAC-­‐IIa	  and	  AAC-­‐IIIb	  are	  so	  similar	  in	  sequences	  it	  is	  likely	  that	  they	  are	  similar	  
in	  structures	  as	  well.	  This	  leaves	  the	  question:	  what	  might	  be	  the	  reason	  for	  having	  such	  distinct	  
substrate	  selectivity?	  	  This	  also	  suggests	  that,	  like	  AAC-­‐IIIb,	  AAC-­‐IIa	  also	  belongs	  to	  the	  GNAT	  
superfamily	  of	  acetyl	  transferases.	  Superimposed	  structures	  of	  the	  AAC-­‐IIa	  and	  AAC-­‐IIIb	  show	  	  	  
remarkable	  similarity	  to	  each	  other	  with	  a	  RMSD	  of	  1.43Å.	  The	  region	  with	  the	  largest	  sequence	  
differences	  between	  these	  two	  proteins	  is	  the	  loop	  region,	  amino	  acids	  202-­‐222	  in	  AAC-­‐IIa	  and	  






Figure	  6:	  Homology-­‐derived,	  overlaid	  structures	  of	  AAC-­‐IIa	  and	  AAC-­‐IIIb.	  Motif	  B,	  the	  GNAT	  
conserved	  acetyl	  acceptor	  site	  is	  shown	  in	  purple	  and	  the	  GNAT	  conserved	  region	  responsible	  
for	  acetyl	  coenzyme	  A	  association	  is	  shown	  in	  yellow	  for	  both	  AAC-­‐IIa	  and	  AAC-­‐IIIb,	  the	  loops	  
for	  AAC-­‐IIa	  and	  AAC-­‐IIIb	  are	  shown	  in	  green	  and	  blue	  respectively.	  Figure	  adapted	  with	  
permission	  from	  Norris,	  A.L.	  and	  E.H.	  Serpersu,	  Ligand	  promiscuity	  through	  the	  eyes	  of	  the	  
aminoglycoside	  N3	  acetyltransferase	  IIa.	  Protein	  science:	  a	  publication	  of	  the	  Protein	  Society,	  
2013.	  22(7):	  p.	  916-­‐28.	  Copyright	  ©	  2013	  The	  Protein	  Society.	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iii.	  Rationale	  of	  this	  study:	  
	   	  
AAC-­‐IIa	  has	  35%	  amino	  acid	  sequence	  identity	  with	  AAC-­‐IIIb,	  but	  in	  contrast	  to	  AAC-­‐IIa,	  
AAC-­‐IIIb	  shows	  significantly	  less	  structural	  change	  associated	  upon	  binding	  of	  
aminoglycosides.	  The	  region	  with	  the	  largest	  sequence	  differences	  between	  these	  two	  
proteins	  is	  the	  loop	  region	  [21].	  Previous	  NMR	  work	  shows	  that	  when	  AAC-­‐IIa	  is	  in	  its	  apo	  
form	  it	  has	  a	  very	  dynamic	  nature,	  seen	  by	  a	  number	  of	  overlapping	  peaks.	  When	  
antibiotics	  such	  as	  tobramycin	  or	  kanamycin,	  bind	  the	  AAC-­‐IIa,	  15N-­‐1H	  heteronuclear	  single	  
quantum	  coherence	  (HSQC)	  spectra	  show	  significant	  increase	  in	  resolution	  and	  chemical	  
shift	  range	  indicating	  a	  well-­‐	  defined	  protein	  structure.	  This	  behavior	  is	  also	  observed	  in	  a	  
high	  promiscuity	  enzyme	  APH	  (3’)-­‐IIIa	  shown	  in	  Figure	  7	  below.	  
	  Studies	  of	  the	  effect	  of	  solvent	  on	  AAC-­‐IIIb-­‐aminoglycoside	  interactions	  have	  revealed	  
an	  interesting	  result	  that	  an	  opposite	  sign	  of	  change	  in	  heat	  capacity	  was	  observed	  when	  
two	  structurally	  similar	  ligands	  were	  bound	  to	  the	  enzyme	  [39].	  Another	  interesting	  
property	  of	  AAC-­‐IIIb	  was	  that	  several	  properties	  of	  the	  ternary	  enzyme-­‐aminoglycoside-­‐
CoASH	  complex	  were	  dependent	  on	  the	  order	  of	  addition	  of	  substrates	  to	  the	  enzyme	  and	  
these	  ternary	  complexes	  were	  not	  identical	  to	  each	  other.	  They	  displayed	  different	  
hydrodynamic	  radii,	  NMR	  spectra	  and	  solvent	  protection	  [40].	  
	  In	  order	  to	  compare	  thermodynamic	  properties	  of	  both	  enzymes,	  we	  initiated	  studies	  
with	  AAC-­‐IIa.	  	  Denaturation	  curve	  on	  AAC-­‐IIa,	  determined	  by	  differential	  scanning	  
calorimetry	  (DSC)	  showed	  multiple	  transitions,	  which	  is	  novel	  amongst	  the	  AGMEs.	  The	  Tm	  
of	  the	  first	  transition	  that	  was	  observed	  on	  the	  unfolding	  curve	  was	  at	  29°C.	  Since	  all	  the	  
previous	  data	  with	  AAC-­‐IIa	  were	  collected	  at	  25	  °C	  examination	  of	  thermodynamics	  of	  AAC-­‐
	  16	  
IIa	  at	  lower	  temperatures	  became	  necessary.	  	  Therefore,	  this	  work	  will	  focus	  on	  examining	  
the	  unfolding	  transitions	  via	  biophysical	  techniques	  and	  the	  thermodynamic	  properties	  of	  
enzyme–ligand	  complexes	  of	  AAC-­‐IIa	  at	  temperatures	  below	  the	  first	  transition	  








Figure	  7:	  1H-­‐15N	  HSQC	  NMR	  spectra	  of	  	  AGMEs	  APH(3’)-­‐IIIa	  and	  AAC-­‐IIIb	  and	  their	  complexes.	  
Apo	  (left)	  ,	  binary	  APH-­‐tobramycin	  (middle)	  and	  binary	  APH-­‐CoFactor	  (right)	  forms	  are	  shown.	  
All	  spectra	  were	  taken	  under	  similar	  experimental	  conditions	  and	  shown	  to	  matching	  contour	  
levels.	  Partial	  figure	  adapted	  with	  permission	  from	  Norris,	  A.L.	  and	  E.H.	  Serpersu,	  Ligand	  
promiscuity	  through	  the	  eyes	  of	  the	  aminoglycoside	  N3	  acetyltransferase	  IIa.	  Protein	  science:	  a	  









Isopropyl-­‐	  β-­‐D-­‐1-­‐thiogalactopyranoside	  (IPTG)	  was	  purchased	  from	  Inalco	  Spa	  (Milano,	  
Italy).	  	  Ion	  exchange	  matrix	  (Macro	  Q)	  was	  purchased	  from	  Bio-­‐Rad	  Laboratories	  (Hercules,	  CA).	  
High	  performance	  Ni-­‐Sepharose	  resin	  was	  purchased	  from	  Amersham	  Biosciences	  (Piscataway,	  
NJ).	  The	  purified	  thrombin	  was	  provided	  by	  Dr.	  Elias	  Fernandez	  (The	  University	  of	  Tennessee)	  or	  
purchased	  from	  Enzyme	  Research	  Laboratories	  (South	  Bend,	  IN).	  99.9%	  deuterium	  oxide	  and	  
99%	  15N	  enriched	  salts	  were	  purchased	  from	  Cambridge	  Isotope	  laboratories	  (Andover,	  MA).	  All	  
the	  other	  reagents	  and	  AGs	  were	  purchased	  from	  Sigma	  -­‐Aldrich	  (St.	  Louis,	  MO)	  at	  the	  highest	  
possible	  purity.	  
	  
ii.	  Overexpression	  and	  purification	  of	  AAC-­‐IIa:	  
	  
The	  AAC-­‐IIa	  protein	  was	  overexpressed	  with	  IPTG	  using	  standard	  protocols	  in	  Luria	  Broth.	  
The	  cells	  were	  harvested	  and	  stored	  at	  -­‐80	  °C	  and	  the	  enzyme	  was	  purified	  within	  two	  weeks	  
from	  these	  cells.	  	  Purification	  of	  the	  AAC-­‐IIa	  was	  performed	  using	  standard	  nickel	  affinity	  
chromatography.	  	  Briefly,	  cells	  were	  suspended	  in	  15	  mL	  of	  lysis	  buffer	  (50mM	  Tris-­‐HCl	  (pH	  7.6),	  
100mM	  NaCl,	  20	  mM	  Imidazole,	  200	  µM	  PMSF	  at	  4°C),	  lysed	  with	  a	  French	  press,	  and	  
centrifuged	  for	  one	  hour	  at	  34,000g.	  The	  supernatant	  was	  then	  passed	  through	  1	  mL	  of	  Ni-­‐
Sepharose	  resin	  where	  the	  AAC-­‐IIa	  was	  eluted	  with	  a	  100-­‐350	  mM	  imidazole	  gradient	  after	  
extensive	  resin	  washing	  (50mM	  Tris-­‐HCl	  (pH	  7.6),	  100mM	  NaCl,	  20	  mM	  Imidazole,	  at	  4°C)	  to	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>98%	  purity.	  The	  6X-­‐	  Histidine	  tag	  was	  removed	  by	  incubation	  with	  thrombin	  for	  3hrs	  at	  25	  °C.	  
Cleaved	  6X-­‐Histidine	  tag	  and	  un-­‐cleaved	  protein	  were	  removed	  by	  passing	  through	  a	  Ni-­‐
Sepharose	  column.	  Histidine	  tag	  free	  protein	  was	  collected	  in	  flow-­‐through.	  Following	  with	  a	  
removal	  of	  thrombin	  by	  ion	  exchange	  chromatography	  where	  an	  increase	  of	  pH	  to	  8.0	  from	  7.6	  
was	  required	  along	  with	  the	  removal	  of	  the	  NaCl	  by	  dialyzing	  it	  against	  50mM	  Tris-­‐HCl,	  pH	  8.0	  
at	  4°C.	  A	  strong	  anion	  exchange	  media	  MacroQ	  was	  used	  for	  this	  chromatography	  with	  an	  
elution	  gradient	  of	  0-­‐750	  mM	  NaCl.	  Lastly,	  the	  fractions	  containing	  AAC-­‐IIa	  were	  dialyzed	  
extensively	  against	  50mM	  MOPS	  (pH	  7.6)	  at	  4°C	  and	  100mM	  NaCl.	  The	  concentration	  of	  AAC-­‐IIa	  
was	  determined	  by	  using	  an	  ε0.1%	  (280nm)	  of	  1.16	  spectrophometrically	  [36].	  
	  
	  
iii.	  Differential	  Scanning	  Calorimetry:	  
	  
Differential	  Scanning	  Calorimetry	  (DSC)	  experiments	  were	  performed	  with	  AAC-­‐IIa	  in	  buffer	  
containing	  50	  mM	  MOPS	  and	  100	  mM	  NaCl	  on	  a	  VP-­‐DSC	  micro	  calorimeter	  from	  MicroCal	  Inc.	  
(Northampton,	  MA).	  The	  melting	  transition	  data	  was	  recorded	  from	  2°C	  to	  65°C	  for	  buffer	  with	  
no	  protein,	  apo,	  binary	  and	  ternary	  complexes	  of	  the	  enzyme.	  For	  the	  binary	  and	  ternary	  
complexes	  the	  protein	  concentration	  was	  maintained	  at	  50	  µM	  while	  the	  ligand	  concentrations	  
were	  such	  that	  the	  enzyme	  was	  >98%	  saturated	  with	  the	  ligand.	  	  	  The	  unfolding	  curve	  for	  apo-­‐
AAC-­‐IIa	  was	  measured	  at	  30,	  50	  and	  70	  µM	  protein	  concentrations.	  The	  reference	  cell	  
contained	  the	  final	  dialysate	  from	  protein	  preparation	  [50	  mM	  MOPS	  buffer	  with	  100mM	  NaCl]	  
at	  pH	  7.6.	  All	  samples	  were	  degassed	  for	  20	  minutes	  prior	  to	  injection.	  Origin	  software	  was	  used	  





Experiments	  were	  performed	  on	  an	  Aviv	  (Lakewood,	  NJ)	  model-­‐202	  spectrometer	  with	  a	  
thermoelectric	  cell	  holder.	  	  20-­‐μM	  protein	  was	  placed	  in	  a	  cuvette	  with	  2.0	  mm	  path	  length.	  For	  
the	  CD	  spectra	  as	  a	  function	  of	  temperature:	  The	  CD	  signal	  was	  measured	  at	  222	  nm	  with	  an	  
increment	  of	  0.2	  °C	  temperatures.	  The	  sample	  was	  equilibrated	  for	  0.2	  minutes	  at	  a	  given	  
temperature	  with	  a	  data	  averaging	  time	  of	  5	  seconds.	  For	  the	  CD	  spectra	  as	  a	  function	  of	  
wavelength:	  The	  CD	  signal	  was	  measured	  over	  a	  wavelength	  range	  of	  260	  -­‐190	  nm	  with	  a	  
wavelength	  step	  of	  0.5nm	  at	  25°C.	  The	  resulting	  spectrum	  was	  an	  average	  of	  four	  scans	  that	  
had	  an	  averaging	  time	  of	  1	  second.	  	  Prior	  to	  all	  data	  collection	  the	  sample	  chamber	  was	  flushed	  
with	  nitrogen	  gas.	  	  
	  
	  
v.Nuclear	  Magnetic	  Resonance:	  
	  
AAC-­‐IIa	  was	  uniformly	  15N-­‐labelled	  using	  M9	  minimal	  media	  containing	  15N	  NH4Cl.	  
Purification	  of	  the	  AAC-­‐IIa	  was	  performed	  using	  the	  method	  described	  previously	  in	  this	  chapter	  
under	  protein	  purification	  (section	  ii).	  	  
For	  NMR	  studies,	  the	  protein	  concentration	  was	  ~130	  µM	  in	  50mM	  MOPS	  and	  100mM	  
NaCl,	  pH	  7.6.	  The	  tobramycin	  (ligand)	  was	  added	  to	  ensure	  >95%	  saturation	  as	  calculated	  from	  
the	  dissociation	  constants	  [41].	  All	  NMR	  experiments	  were	  performed	  using	  a	  600-­‐MHz,	  Varian	  
Inova	  spectrometer	  equipped	  with	  a	  1H,	  13C,	  15N	  triple	  detection,	  salt	  tolerant	  cryogenic	  probe	  
at	  the	  University	  of	  Tennessee.	  Sensitivity	  enhanced	  1H-­‐15N	  HSQC	  (heteronuclear	  single-­‐
	  20	  
quantum	  coherence)	  correlation	  spectra	  [42]	  were	  recorded	  with	  a	  sweep	  width	  of	  2434	  Hz	  in	  
proton	  dimension,	  64	  increments	  and	  296	  or	  more	  transients	  were	  acquired	  per	  slice.	  
Data	  were	  processed	  with	  NMRpipe	  Software	  [43].	  	  FID	  was	  multiplied	  with	  a	  sin2	  
window	  function	  in	  the	  acquisition	  dimension	  before	  Fourier	  transformation.	  No	  baseline	  
correction	  or	  other	  cosmetic	  procedures	  were	  applied.	  Spectra	  were	  exported	  to	  Sparky	  (T.D.	  
Goddard	  and	  D.G.	  Kneller,	  SPARKY	  3,	  University	  of	  California,	  San	  Francisco)	  for	  analysis	  and	  
display.	  Enzymatic	  activities	  were	  determined	  before	  and	  after	  experiments	  and	  were	  >80%	  of	  
the	  original	  activity.	  
	  
	  
vi.	  Analytical	  Ultra-­‐Centrifugation:	  
	  
The	  sedimentation	  velocity	  (SV)	  was	  performed	  in	  a	  Beckman	  XL-­‐I	  analytical	  ultracentrifuge.	  
Prior	  to	  centrifugation,	  the	  protein	  was	  dialyzed	  into	  50mM	  MOPS	  (pH	  7.6)	  and	  100mM	  NaCl,	  
and	  the	  resulting	  dialysate	  was	  used	  as	  the	  reference	  solution.	  After	  the	  addition	  of	  CoASH	  
and/or	  aminoglycoside,	  400	  µL	  samples	  were	  placed	  in	  double-­‐sector	  charcoal-­‐filled	  epon	  cells.	  
Samples	  were	  equilibrated	  for	  2	  hours	  under	  vacuum	  at	  12°C	  and	  25	  °C	  and	  then	  run	  for	  8	  
hours	  at	  5000	  rpm.	  	  Sedimentation	  of	  the	  enzyme	  was	  monitored	  by	  absorbance	  at	  280nm.	  
Sedimentation	  coefficients	  were	  determined	  by	  sedimentation	  coefficient	  distribution	  (c(s))	  
analysis	  using	  SEDFIT	  [44,	  45]	  and	  the	  size	  distribution	  analysis	  of	  macromolecules	  was	  




vii.	  Isothermal	  Titration	  Calorimetry:	  
	  
Isothermal	  Titration	  Calorimetry	  (ITC)	  Experiments	  were	  performed	  on	  a	  VP-­‐ITC	  micro	  
calorimeter	  purchased	  from	  Microcal,	  Inc.	  (Northampton,	  MA),	  at	  varying	  temperatures	  in	  a	  
range	  of	  4	  –	  29°C.	  AAC-­‐IIa	  concentrations	  were	  between	  20-­‐30µM	  for	  the	  maintenance	  of	  c	  
values	  ([Binding	  sites]	  x	  association	  constant)	  within	  the	  range	  of	  1-­‐100	  for	  greater	  accuracy	  of	  
association	  constant	  (KA)	  measurements.	  The	  titrant	  solutions	  were	  prepared	  with	  desulphated	  
aminoglycoside	  diluted	  into	  the	  final	  dialysis	  buffer	  used	  in	  the	  enzyme	  purification	  allowing	  
both	  cell	  and	  syringe	  solutions	  to	  contain	  100mM	  NaCl	  and	  50mM	  of	  pH	  7.6	  MOPS	  at	  respective	  
temperatures.	  	  Samples	  were	  degassed	  for	  10	  minutes	  before	  being	  loaded	  on	  to	  the	  
instrument.	  	  The	  pH	  of	  each	  cell	  and	  syringe	  solution	  was	  checked	  before	  and	  after	  each	  
experiment	  and	  no	  change	  was	  noticed.	  Titrations	  of	  substrate	  into	  enzyme	  solution	  consisted	  
of	  29	  injections	  of	  10µl,	  separated	  by	  240	  seconds	  with	  a	  cell	  stirring	  speed	  of	  300rpm.	  The	  
reference	  power	  was	  set	  to	  10	  µcal	  per	  second.	  The	  enzymatic	  activity	  of	  AAC-­‐IIa	  was	  
determined	  before	  and	  after	  each	  experiment.	  	  In	  all	  cases	  the	  enzyme	  activity	  remained	  
greater	  than	  85%	  of	  the	  starting	  activity.	  	  
Thermograms	  were	  integrated	  using	  the	  Origin	  software	  provided	  by	  the	  instrument	  
manufacturer	  and	  the	  best	  fits	  were	  obtained	  using	  one-­‐site	  binding.	  This	  data	  was	  also	  
analyzed	  using	  the	  SEDPHAT	  [46]and	  NITPIC[47]	  softwares.	  The	  thermograms	  shown	  in	  figures	  
are	  taken	  from	  the	  Origin	  software.	  Dissociation	  constants	  (KD)	  values	  were	  calculated	  form	  the	  
association	  constants	  (KA)	  derived	  from	  fitted	  titration	  curves.	  The	  slope	  of	  plot	  of	  ΔHobs	  versus	  
temperature	  was	  used	  to	  determine	  the	  change	  in	  heat	  capacity	  (ΔCp).	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viii.	  Kinetic	  Assays:	  
	  
The	  kinetic	  parameters	  for	  the	  AAC-­‐IIa	  activity	  were	  determined	  by	  using	  a	  continuous	  
assay	  to	  determine	  enzyme	  activity,	  which	  utilizes	  the	  coupled	  reaction	  described	  below.	  	  
	  
Tobramycin	  +	  Acetyl	  CoA	  →	  3-­‐Acetyl-­‐	  Tobramycin	  +CoASH	  
4,4ʹ′	  -­‐	  Dipyridyl	  disulfide	  +	  CoASH	  →	  CoA	  –S-­‐S-­‐pyridine	  +	  pyridine	  -­‐4-­‐thiolate.	  
	  
Activity	  of	  this	  enzyme	  is	  measured	  based	  on	  the	  reduction	  of	  4,4ʹ′	  -­‐	  Dipyridyl	  disulfide	  
by	  CoASH,	  releasing	  pyridine-­‐4-­‐thiolate,	  which	  can	  easily	  be	  detected	  at	  324	  nm	  
spectrophometrically	  [48].	  The	  concentration	  of	  AAC-­‐IIa	  was	  determined	  by	  using	  a	  ε0.1%	  
(280nm)	  of	  1.16	  spectrophometrically.	  This	  was	  done	  using	  a	  Cary-­‐Win	  UV-­‐vis	  
spectrophotometer	  (Varian,	  Palo	  Alto,	  CA).	  Samples	  comprised	  of	  100mM	  NaCl	  and	  50mM	  
MOPS,	  pH	  7.6	  at	  varying	  temperatures.	  AAC-­‐IIa	  (10nM)	  was	  used	  in	  each	  assay,	  and	  the	  
reaction	  was	  initiated	  by	  addition	  of	  aminoglycoside	  tobramycin	  and	  substrate	  AcCoA	  
concentration	  was	  held	  at	  the	  saturating	  level	  of	  100	  µM.	  Michaelis-­‐Menten	  type	  kinetics	  were	  
followed	  for	  the	  reaction	  with	  the	  substrate	  [26],	  where	  the	  substrate	  inhibition	  allowed	  data	  
to	  fit	  the	  equation,	  ν	  =	  (	  Vmax[S])	  /	  (Km	  +[S]	  +	  [S]2/Ki),	  where	  ν	  is	  the	  initial	  velocity,	  	  Vmax	  is	  the	  
maximal	  velocity,	  	  Km	  	  is	  the	  Michaelis	  constant,	  and	  	  Ki	  is	  the	  substrate	  inhibition	  constant.	  	  
Turnover	  rates	  (kcat)	  were	  calculated	  from	  the	  relationship	  Vmax	  	  	  =	  kcat	  [E]T.	  All	  data	  were	  




III.	  Results	  and	  Discussion	  
	  
i.	  The	  unfolding	  of	  AAC-­‐IIa	  shows	  multiple	  transitions	  	  
	  
To	  initiate	  the	  comparative	  studies	  between	  the	  AAC-­‐IIa	  and	  the	  AAC-­‐IIIb,	  we	  started	  with	  
the	  measurement	  of	  their	  melting	  temperatures	  	  (Tm).	  The	  melting	  temperature	  is	  the	  
temperature	  at	  which	  each	  transition	  is	  50	  percent	  complete.	  For	  protein	  denaturation	  the	  Tm	  is	  
the	  temperature	  at	  which	  50	  percent	  of	  the	  protein	  is	  unfolded	  and,	  assuming	  a	  two-­‐state	  
process,	  the	  remaining	  50	  is	  still	  in	  its	  native	  form	  or	  folded	  [49].	  Thermal	  transitions	  of	  AAC-­‐IIa	  
in	  its	  apo,	  binary	  and	  ternary	  complexes	  were	  examined	  using	  differential	  scanning	  Calorimetry	  
(DSC)	  over	  the	  temperature	  range	  of	  2-­‐65	  °C.	  The	  DSC	  traces	  for	  AAC-­‐IIa	  were	  not	  reversible;	  
hence	  only	  Tm	  has	  been	  measured	  for	  qualitative	  conclusions.	  Table	  1	  below	  notes	  the	  melting	  
temperatures	  of	  all	  the	  complexes	  of	  AAC-­‐IIa.	  	  
DSC	  studies	  were	  performed	  with	  an	  enzyme	  concentration	  of	  50	  μM	  and	  a	  control	  run	  was	  
performed	  with	  buffer	  solution	  as	  reference.	  Apo-­‐AAC-­‐IIa	  yielded	  a	  melting	  temperature	  of	  43.9	  
°C.	  When	  a	  binary	  complex	  was	  formed	  with	  aminoglycoside	  tobramycin	  the	  melting	  
temperature	  was	  determined	  to	  be	  44.7°C.	  The	  binary	  enzyme–CoASH	  complex	  yielded	  a	  Tm	  
value	  of	  43.1°C.	  The	  melting	  temperature	  shift	  was	  0.8°C	  higher	  with	  AAC-­‐IIa	  –tobramycin	  
complex	  and	  0.8°C	  lower	  for	  AAC-­‐IIa-­‐CoASH	  complex	  as	  compared	  to	  apo-­‐AAC-­‐IIa.	  This	  shift	  is	  
not	  significant,	  and	  hence	  it	  can	  be	  concluded	  that	  binding	  of	  ligands	  does	  not	  shift	  the	  Tm	  of	  
AAC-­‐IIa;	  i.e.	  the	  net	  unfolded	  protein	  in	  apo	  or	  ligand	  bound	  forms	  stays	  the	  same	  at	  that	  given	  
temperature	  (Figure	  8).	  	  Such	  was	  not	  the	  case	  in	  the	  AGME	  AAC-­‐IIIb.	  Apo-­‐AAC-­‐IIIb,	  gave	  a	  Tm	  of	  
39.5°C	  while	  when	  bound	  to	  the	  aminoglycoside	  neomycin,	  the	  Tm	  drastically	  shifts	  to	  44.8°C	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[40].	  This	  is	  another	  major	  difference	  between	  the	  two	  enzymes	  AAC-­‐IIa	  and	  AAC-­‐IIIb	  that	  share	  
70	  percent	  sequence	  similarity	  with	  each	  other.	  AAC-­‐IIa	  at	  the	  end	  of	  the	  run	  aggregates	  in	  
both	  its	  apo	  and	  ligand	  bound	  form	  and	  thus	  the	  denaturation	  curve	  is	  not	  reversible	  and	  the	  





Figure	  8:	  Denaturation	  curves	  of	  enzymes	  AAC-­‐IIa	  (left)	  and	  AAC-­‐IIIb	  (right)	  in	  their	  apo	  and	  





However,	  while	  examining	  melting	  of	  AAC-­‐IIa,	  using	  DSC,	  a	  novel	  phenomenon	  was	  noticed	  
amongst	  the	  AGMEs,	  two	  separate	  transitions	  were	  observed	  on	  the	  denaturation	  curve	  of	  
AAC-­‐IIa.	  The	  unfolding	  curve	  of	  apo-­‐AAC-­‐IIa	  showed	  two	  separate	  transitions	  with	  the	  melting	  
temperatures	  of	  29	  °C	  and	  43.9	  °C	  respectively	  (Figure	  9).	  Different	  concentrations	  of	  the	  
enzyme	  were	  examined	  to	  check	  for	  a	  concentration-­‐dependent	  behavior	  if	  any.	  Apo-­‐AAC-­‐IIa	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was	  scanned	  at	  30,	  50	  and	  70	  µM’s	  respectively.	  All	  three	  concentrations	  led	  to	  the	  same	  
melting	  temperatures	  showing	  a	  similar	  unfolding	  pattern	  (Figure	  9-­‐top	  panel).	  	  	  
To	  see	  the	  effect	  of	  addition	  of	  ligand	  to	  AAC-­‐IIa,	  the	  thermal	  transitions	  of	  the	  binary	  
complexes	  of	  AAC-­‐IIa	  were	  examined	  (Figure	  9,	  middle	  panel).	  	  	  Multiple	  transitions	  are	  
observed	  below	  the	  Tm	  for	  both	  the	  binary	  complexes	  similar	  to	  the	  apo	  AAC-­‐IIa.	  These	  
observations	  state	  that	  the	  enzyme	  is	  undergoing	  various	  conformational	  changes	  at	  lower	  
temperatures.	  At	  least	  one	  of	  the	  additional	  transitions	  at	  low	  temperature	  range,	  observed	  
with	  both	  binary	  complexes,	  may	  represent	  dissociation	  of	  the	  ligand	  from	  the	  protein.	  	  This	  is	  a	  
novel	  observation	  amongst	  the	  AGMEs.	  The	  sequence	  homolog	  AAC-­‐IIIb	  does	  not	  show	  such	  
additional	  transitions	  in	  apo	  or	  ligand-­‐bound	  forms	  and	  also	  unlike	  AAC-­‐IIa,	  upon	  binary	  
complex	  formation	  the	  Tm	  shifts	  higher	  in	  a	  ligand-­‐dependent	  manner.	  	  
The	  thermal	  transitions	  of	  the	  ternary	  complexes	  of	  AAC-­‐IIa	  were	  also	  examined	  by	  using	  
DSC.	  (Figure	  9,	  bottom	  panel)	  Interestingly,	  upon	  formation	  of	  ternary	  complexes,	  regardless	  of	  
the	  order	  of	  the	  complex	  formation,	  the	  melting	  temperature	  shifts	  drastically.	  For	  the	  addition	  
of	  CoASH	  to	  the	  AAC-­‐IIa-­‐tobramycin	  complex,	  the	  melting	  temperature	  is	  54.1°C	  and	  for	  the	  
addition	  of	  tobramycin	  to	  the	  AAC-­‐IIa-­‐CoASH	  complex	  the	  melting	  temperature	  is	  58.8°C.	  
Similar	  to	  the	  unfolding	  pattern	  of	  apo	  and	  binary	  complexes	  of	  AAC-­‐IIa,	  the	  ternary	  complexes	  
also	  showed	  multiple	  transitions	  below	  Tm.	  Both	  ternary	  complexes	  show	  a	  significant	  upshift	  as	  
compared	  to	  the	  apo	  and	  binary	  complexes	  of	  AAC-­‐IIa.	  Hence,	  ternary	  complex	  formation	  is	  
required	  to	  increase	  the	  melting	  temperature	  for	  AAC-­‐IIa,	  which	  is	  unlike	  AAC-­‐IIIb	  where	  a	  
binary	  complex	  formation	  is	  sufficient	  to	  shift	  the	  melting	  temperature.	  These	  are	  also	  
reminiscent	  of	  the	  differences	  between	  the	  ternary	  complexes	  of	  AAC-­‐IIIb	  that	  are	  formed	  by	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reversing	  the	  addition	  of	  ligands	  to	  the	  enzyme	  suggesting	  that	  such	  property	  may	  be	  more	  
general	  than	  being	  specific	  for	  AAC-­‐IIIb.	  NMR	  spectra	  of	  ternary	  complexes	  of	  AAC-­‐IIa,	  show	  
well	  dispersed	  spectra	  indicative	  of	  more	  structure	  and	  less	  flexibility	  at	  both	  12°C	  and	  29°C.	  
However,	  it	  is	  seen	  that	  at	  12°C,	  lower	  temperature,	  a	  ternary	  complex	  is	  a	  must	  for	  AAC-­‐IIa	  to	  
gain	  structure.	  	  
This	  observation	  of	  multiple	  transitions	  is	  indicative	  of	  various	  conformational	  changes	  that	  
AAC-­‐IIa	  undergoes	  at	  low	  temperatures.	  The	  final	  transition	  of	  apo	  AAC-­‐IIa	  is	  higher	  than	  that	  of	  
the	  AAC-­‐IIIb,	  even	  though	  the	  AAC-­‐IIa	  is	  more	  flexible.	  This	  suggests	  that	  the	  core	  structure	  of	  





Table	  1:	  Melting	  temperatures	  acquired	  using	  differential	  scanning	  Calorimetry	  
Complex	   Melting	  Temperature	  [°C]	  
Apo-­‐AAC-­‐IIa	   43.9	  
AAC-­‐IIa+Tobramycin	   44.7	  
AAC-­‐IIa-­‐CoASH	   43.1	  
[AAC-­‐IIa+Tobramycin]+CoASH	   54.1	  







Figure	  9:	  Unfolding	  curves	  showing	  multiple	  transitions	  of	  AAC-­‐IIa	  in	  its	  apo	  (top	  panel)	  and	  






ii.Melting	  temperatures	  of	  apo-­‐AAC-­‐IIa	  compared	  to	  its	  binary	  complexes	  are	  similar	  
	  
To	  follow	  the	  α-­‐helical	  melting,	  unfolding	  curves	  of	  AAC-­‐IIa	  were	  observed	  using	  circular	  
Dichroism	  (CD)	  spectroscopy.	  AAC-­‐IIa	  does	  not	  yield	  a	  reversible	  signal	  as	  the	  protein	  
aggregates,	  hence	  only	  the	  midpoint	  of	  unfolding	  transition	  (Tm)	  was	  determined	  in	  this	  
study.	  Here,	  unfolding	  curves	  of	  AAC-­‐IIa	  in	  its	  apo	  and	  binary	  complexes	  with	  tobramycin	  
and	  CoASH	  were	  tested.	  Changes	  in	  α-­‐helical	  content	  of	  the	  enzyme	  were	  followed	  at	  
222nm	  as	  a	  function	  of	  temperature.	  A	  sigmoidal	  curve	  pattern	  is	  observed	  for	  unfolding	  
curves	  of	  all	  three	  complexes	  being	  tested	  (Figure	  10).	  The	  melting	  temperature	  was	  
determined	  from	  the	  mid	  points	  of	  these	  transition	  curves	  by	  using	  standard	  curve	  fitting	  
procedure	  for	  a	  two-­‐state	  process.	  Table	  2	  notes	  all	  the	  three	  melting	  temperature	  acquired	  
from	  the	  CD	  analysis.	  One	  aspect	  of	  the	  data	  was	  consistent	  with	  DSC	  measurements,	  which	  
are	  the	  midpoints	  of	  transitions	  did	  not	  show	  any	  effect	  of	  bound	  ligands	  and	  all	  yielded	  
superimposable	  data.	  
Tm	  values	  determined	  by	  CD	  spectroscopy	  were	  ~10°C	  higher	  than	  those	  determined	  by	  
DSC.	  	  CD	  spectra	  were	  collected	  as	  a	  function	  of	  wavelength	  to	  monitor	  the	  residual	  α-­‐
helical	  content.	  Spectra	  showing	  the	  α-­‐helical	  content	  of	  apo	  AAC-­‐IIa	  at	  selected	  
temperatures	  are	  shown	  in	  figure	  10	  (bottom	  left	  panel).	  CD	  spectra	  acquired	  with	  the	  apo-­‐
and	  ligand-­‐bound	  forms	  of	  the	  enzyme	  at	  temperatures	  corresponding	  to	  Tm	  determined	  by	  
DSC	  revealed	  the	  presence	  of	  residual	  α-­‐helical	  content	  for	  all	  complexes.	  The	  dip	  in	  figure	  
10	  (bottom	  right	  panel)	  at	  222	  nm	  shows	  the	  presence	  of	  α-­‐helical	  content	  at	  45°C,	  a	  
temperature	  above	  the	  Tm	  determined	  on	  DSC.	  The	  residual	  α-­‐helical	  content	  at	  these	  
temperatures	  might	  be	  protected	  due	  to	  aggregation	  and/or	  oligomerization.	  Required	  
	  29	  
temperature	  for	  the	  observation	  of	  spectra	  representing	  random	  coil	  was	  60°C.	  These	  data	  
are	  consistent	  with	  AAC-­‐IIa	  being	  a	  highly	  flexible	  enzyme.	  It	  also	  suggest	  that	  unfolding	  of	  
AAC-­‐IIa	  occurs	  in	  multiple	  stages	  which	  may	  include	  unfolding	  of	  protein	  domains	  
independent	  of	  each	  other	  and	  even	  at	  higher	  temperatures	  beyond	  Tm,	  the	  enzyme	  still	  
contains	  a	  structured	  core.	  	  
	  
	  
Table	  2:	  Melting	  temperature	  measured	  via	  circular	  dichroism	  
	  
Complex	   Tm	  (°C)	  
Apo-­‐AAC-­‐IIa	   54.5	  ±	  0.1	  
AAC-­‐IIa-­‐Tobramycin	   53.6	  ±	  0.1	  





















Figure	  10:	  CD	  spectra	  of	  AAC-­‐IIa:	  Unfolding	  of	  apo	  AAC-­‐IIa	  and	  its	  binary	  complexes	  as	  a	  
function	  of	  temperature	  acquired	  via	  CD	  (top	  panel);	  (bottom	  panel)	  (left)	  spectra	  showing	  the	  





iii.Thermodynamics	  of	  AAC-­‐IIa	  at	  low	  temperatures	  
	  
To	  determine	  thermodynamic	  properties	  of	  the	  formation	  of	  enzyme	  ligand	  complexes	  
at	  temperatures	  below	  the	  first	  calorimetric	  transition	  peak,	  we	  titrated	  the	  enzyme	  with	  the	  
tightest	  binding	  aminoglycoside	  tobramycin	  in	  studies	  with	  isothermal	  titration	  calorimetry	  
(ITC).	  	  An	  example	  of	  ITC	  data	  is	  shown	  in	  figure	  11	  below.	  ITC	  data	  was	  collected	  over	  a	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temperature	  range	  of	  9-­‐29°C	  and	  is	  noted	  in	  table	  3	  below.	  The	  binding	  affinity	  of	  tobramycin	  
to	  the	  enzyme	  AAC-­‐IIa	  decreases	  with	  increasing	  temperature.	  For	  instance,	  at	  12°C,	  the	  
tightest	  binding	  with	  a	  KD	  of	  12.2	  ±	  0.2	  μM	  is	  observed,	  while	  the	  dissociation	  constant	  at	  29	  °C	  
becomes	  50.2	  ±	  1.1	  μM.	  The	  binding	  enthalpies	  show	  more	  complex	  temperature	  dependence.	  
For	  a	  temperature	  range	  of	  9-­‐20	  °C,	  the	  ΔHobs	  fluctuates	  within	  a	  small	  range	  of	  	  -­‐5.6	  and	  -­‐8.6	  
kcal	  mol-­‐1,	  however	  for	  temperatures	  above	  20	  °C	  a	  bigger	  shift	  has	  been	  observed,	  suggesting	  
that	  refolding	  or	  conformational	  changes	  of	  enzyme	  contributes	  to	  the	  observed	  enthalpy	  and	  
contribution	  of	  refolding	  enthalpy	  steeply	  increased	  up	  to	  the	  melting	  temperature.	  These	  
observations	  are	  consistent	  with	  NMR	  data	  where	  the	  binding	  of	  ligands	  cause	  the	  enzyme	  to	  
adopt	  a	  well-­‐defined	  structure	  at	  29°C.	  No	  binding	  was	  observed	  for	  above	  35°C	  presumably	  
the	  active	  site	  is	  completely	  unfolded	  hence	  not	  capable	  of	  binding	  ligand.	  	  
Heat	  capacity	  is	  one	  of	  the	  major	  thermodynamic	  quantities	  that	  are	  measured	  in	  
proteins	  and	  protein–ligand	  interactions.	  The	  change	  in	  heat	  capacity	  (ΔCp)	  is	  determined	  from	  
the	  slope	  of	  the	  enthalpy	  versus	  temperature	  plots	  that	  are	  usually	  linear	  within	  a	  short	  
temperature	  range.	  Since	  the	  binding	  enthalpy	  includes	  contributions	  at	  higher	  temperatures,	  
we	  performed	  ligand	  binding	  at	  temperature	  well	  below	  the	  first	  transition	  temperature	  
observed	  in	  DSC	  traces.	  For	  temperatures	  9-­‐20°C,	  where	  there	  is	  no	  contribution	  of	  enthalpy	  
from	  conformational	  changes	  or	  refolding	  of	  the	  enzyme,	  the	  ΔH	  varies	  within	  a	  small	  range	  of	  -­‐
5.6	  to	  -­‐8.6	  kcal	  mol-­‐1	  (Figure	  12).	  ΔCp	  of	  -­‐0.19	  ±	  0.1	  kcal	  mol-­‐1	  K-­‐1	  was	  determined	  from	  the	  slope	  
of	  the	  line	  from	  ΔH	  versus	  T	  for	  the	  temperature	  range	  below	  20°C	  (Figure	  13).	  	  This	  negative	  
value	  of	  ΔCp	  suggests	  that	  the	  protein	  becomes	  “tighter”	  with	  increasing	  temperature	  and	  
either	  more	  hydrophobic	  groups	  are	  buried	  or	  more	  hydrophilic	  groups	  are	  exposed	  to	  solvent	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or	  both.	  	  Since	  the	  folding	  enthalpy	  of	  the	  protein	  starts	  to	  contribute	  to	  the	  measured	  
enthalpy,	  the	  change	  in	  heat	  capacity	  above	  20°C	  is	  not	  determined.	  Below	  20°C,	  the	  binding	  
enthalpy	  does	  not	  appear	  to	  have	  contribution	  of	  the	  folding	  enthalpy.	  The	  value	  of	  ΔCp	  below	  
20°C,	  is	  also	  similar	  to	  those	  determined	  for	  the	  carbohydrate-­‐protein	  interactions,	  which	  are	  
typically	  in	  the	  range	  of	  -­‐0.1—	  -­‐0.5	  kcal	  mol-­‐1	  K-­‐1.	  Like	  AAC-­‐IIa,	  the	  change	  in	  heat	  capacity	  for	  
AAC-­‐IIIb	  is	  also	  similar	  to	  values	  observed	  in	  carbohydrate-­‐protein	  interactions	  [50].	  Low	  




Table	  3:	  Thermodynamic	  parameters	  of	  AAC-­‐IIa	  binary	  complex	  with	  aminoglycoside	  
Tobramycin.	  	  
	  
Temperature	  (°C)	   KD	  	  (μM)	  
ΔHobs	   ΔCp	  (H20)	  
(kcal	  mol-­‐1)	   (kcal	  mol-­‐1	  K-­‐1)	  
9	   23.0	  ±	  0.6	   -­‐6.6	  ±	  0.6	   	  	  
10	   20.3	  ±	  0.6	   -­‐7.3	  ±	  0.6	   -­‐0.19	  ±	  0.1	  	  
12	   12.2	  ±	  0.2	   -­‐6.2	  ±	  0.3	  
	  13	   23.2	  ±	  0.8	   -­‐5.6	  ±	  0.3	  
	  15	   14.5	  ±	  0.4	   -­‐7.7	  ±	  0.3	   	  	  
17	   24.2	  ±	  0.3	   -­‐7.1	  ±0.5	   	  	  
18	   15.9	  ±	  0.4	   -­‐8.7	  ±	  0.4	   	  	  
20	   21.6	  ±	  0.3	   -­‐8.6	  ±	  0.7	   	  	  
21	   42.5	  ±	  2.2	   -­‐18.0	  ±	  1.8	   	  	  
22	   38.5	  ±	  0.2	   -­‐16.3	  ±	  2.1	   	  	  
24	   69.7	  ±	  2.1	   -­‐52.3	  ±	  2.3	   	  	  
27	   46.9	  ±	  1.2	   -­‐57.5	  ±	  2.6	   	  	  







	   	  	  
	   	  
	  
Figure	  11:	  Typical	  thermogram	  (top)	  and	  isotherm	  (bottom)	  for	  titration	  of	  tobramycin	  into	  AAC-­‐
IIa.	  Time	  integration	  of	  the	  thermal	  power	  yields	  the	  heat	  of	  injection.	  In	  the	  isotherms,	  data	  


















Figure	  13:	  Determination	  of	  heat	  capacity	  change	  from	  the	  slope	  of	  the	  line	  obtained	  from	  







iv.	  Effect	  of	  temperature	  on	  the	  structure	  and	  complex	  formation	  of	  AAC-­‐IIa.	  
	  
The	  ITC	  data	  described	  in	  section	  iii	  show	  a	  tighter	  binding	  of	  aminoglycoside	  to	  AAC-­‐IIa	  
at	  lower	  temperatures.	  In	  light	  of	  these	  data	  we	  hypothesized	  that	  AAC-­‐IIa	  may	  be	  more	  
structured	  at	  temperatures	  below	  the	  first	  observed	  transition	  at	  29°C.	  Hence,	  we	  studied	  AAC-­‐
IIa	  using	  nuclear	  magnetic	  resonance	  (NMR)	  at	  low	  temperatures.	  If	  this	  transition	  represents	  
conversion	  of	  more	  structured	  regions	  of	  the	  protein	  to	  a	  more	  dynamic	  state,	  then	  the	  
expectation	  is	  that	  the	  NMR	  spectra	  acquired	  below	  the	  transition	  temperature	  may	  reveal	  that	  
AAC-­‐IIa	  is	  indeed	  more	  structured	  at	  lower	  temperatures.	  NMR	  spectra	  were	  acquired	  and	  
compared	  at	  12°C	  well	  below	  the	  first	  transition	  observed	  in	  DSC	  and	  at	  29°C,	  in	  its	  apo,	  binary	  
and	  ternary	  complexes.	  Dynamic	  properties	  of	  a	  protein	  have	  profound	  effect	  on	  NMR	  spectra.	  
This	  occurrence	  of	  a	  highly	  overlapped	  spectrum	  is	  a	  result	  of	  several	  backbone	  amide	  groups	  
being	  in	  a	  very	  similar	  chemical	  environment	  indicative	  of	  protein	  being	  highly	  dynamic	  and	  
adopting	  multiple	  conformations	  or	  has	  intrinsically	  disordered	  domains.	  However,	  the	  overall	  
shifts	  and	  changes	  in	  the	  spectrum	  can	  still	  be	  examined.	  	  
	  	  Figure	  14	  is	  a	  representative	  of	  1H-­‐15N	  heteronuclear	  single	  quantum	  coherence	  (HSQC)	  
spectra	  of	  apo	  AAC-­‐IIa	  acquired	  at	  12°C	  (spectra	  in	  red)	  and	  29°C	  (spectra	  in	  green).	  Peaks	  are	  
observed	  between	  a	  short	  chemical	  shift	  range	  of	  7.21	  to	  8.40	  ppm	  on	  the	  proton	  (1H)	  x-­‐	  axis	  
and	  between	  110.00	  and	  125.00	  ppm	  on	  the	  (15N)	  y-­‐axis,	  yielding	  a	  highly	  overlapped	  spectrum.	  
Examining	  the	  apo	  spectra	  at	  29°C	  also	  shows	  a	  similar	  overlapped	  spectrum.	  Both	  spectra	  are	  
indicative	  of	  highly	  dynamic	  protein	  at	  both	  temperatures.	  This	  observation	  strongly	  suggests	  
that	  the	  transition	  at	  29°C	  does	  not	  represent	  the	  conversion	  of	  a	  structured	  domain	  into	  a	  
more	  flexible	  one.	  	  But	  may	  be	  indicative	  of	  a	  conformational	  change	  that	  may	  also	  include	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Figure	  14:	  NMR	  spectra	  of	  15N	  labeled	  apo	  AAC-­‐IIa:	  (left)	  spectra	  acquired	  at	  12°C	  in	  red	  and	  




To	  check	  how	  the	  structure	  of	  AAC-­‐IIa	  changes	  upon	  the	  addition	  of	  ligand	  NMR	  spectra	  
of	  binary	  complexes	  with	  aminoglycoside	  tobramycin	  and	  co-­‐substrate	  CoASH	  are	  collected	  at	  
both	  12°C	  and	  29°C.	  Spectra	  obtained	  from	  the	  binary	  complexes	  are	  shown	  in	  figure	  15.	  
Presence	  of	  ligands	  tobramycin	  (bottom	  panel)	  and	  CoASH	  (top	  panel)	  led	  to	  increase	  in	  the	  
resolution	  of	  the	  spectrum	  acquired	  with	  the	  apo	  protein	  at	  29°C	  and	  a	  relatively	  smaller	  
changes	  in	  the	  spectrum	  collected	  at	  12°C.	  The	  12°C	  spectrum	  still	  maintained	  the	  highly	  
overlapped	  character.	  Compared	  to	  CoASH,	  addition	  of	  tobramycin	  led	  to	  a	  little	  more	  
dispersion	  of	  spectrum	  at	  12°C	  giving	  a	  better	  resolution.	  This	  phenomenon	  is	  reversed	  when	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the	  binary	  complexes	  were	  examined	  at	  29°C.	  	  A	  better	  resolution	  is	  achieved	  upon	  binding	  of	  
the	  co-­‐substrate	  CoASH	  as	  compared	  to	  the	  aminoglycoside	  tobramycin.	  	  Binding	  of	  the	  ligands	  
leads	  to	  some	  peak	  dispersion,	  however	  the	  spectra	  still	  remains	  overlapped.	  This	  suggests	  that	  
AAC-­‐IIa	  is	  still	  flexible	  and	  unstructured.	  These	  results	  are	  unlike	  AAC-­‐IIIb.	  NMR	  spectra	  show	  
AAC-­‐IIIb	  is	  structured	  in	  its	  apo	  form.	  Addition	  of	  ligands	  show	  some	  dispersion	  but	  overall	  AAC-­‐






Figure	  15:	  NMR	  spectra	  of	  binary	  complexes	  of	  15N	  labeled	  AAC-­‐IIa	  at	  12°C	  	  (red)	  and	  29°C	  
(green):	  (top)	  AAC-­‐IIa-­‐CoASH,	  (bottom)	  AAC-­‐IIa-­‐	  Tobramycin.	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To	  observe	  the	  effect	  of	  formation	  of	  ternary	  complexes	  on	  the	  structure	  and	  dynamics	  
of	  AAC-­‐IIa,	  NMR	  spectra	  were	  acquired.	  Spectra	  were	  collected	  on	  the	  ternary	  complexes	  that	  
were	  formed	  differently	  meaning	  to	  an	  AAC-­‐IIa–co-­‐substrate	  complex,	  tobramycin	  was	  added	  
and	  to	  AAC-­‐IIa-­‐tobramycin	  complex	  CoASH	  were	  added	  (Figure	  13).	  	  NMR	  spectrum	  of	  AAC-­‐IIa,	  
acquired	  at	  12°C	  showed	  the	  highest	  dispersion	  in	  the	  ternary	  complexes	  indicating	  that	  both	  
substrates	  are	  required	  for	  this	  enzyme	  to	  adopt	  a	  well-­‐defined	  structure	  in	  solution.	  This	  is	  in	  
contrast	  to	  its	  behavior	  at	  29°C,	  where	  either	  CoASH	  or	  tobramycin	  alone	  can	  lead	  to	  a	  well-­‐
dispersed	  spectra.	  The	  spectra,	  acquired	  with	  ternary	  complexes,	  showed	  that	  there	  is	  slightly	  
higher	  dispersion	  at	  both	  temperatures	  when	  CoASH	  binds	  to	  the	  enzyme	  first	  followed	  by	  
tobramycin	  as	  compared	  to	  a	  ternary	  complex	  formed	  by	  addition	  of	  tobramycin	  first.	  Well-­‐
dispersed	  spectra	  are	  obtained	  in	  both	  the	  complexes	  at	  both	  the	  temperatures.	  This	  is	  an	  
interesting	  property	  of	  AAC-­‐IIa	  at	  29°C	  addition	  of	  each	  ligand	  alone	  yields	  a	  well-­‐dispersed	  
spectra,	  however	  both	  ligand	  and	  the	  co-­‐substrate	  are	  required	  to	  obtain	  good	  resolution	  at	  
12°C.	  This	  indicates	  that	  the	  conformations	  at	  29°C	  are	  much	  more	  responsive	  to	  the	  addition	  
of	  ligands,	  while	  the	  ones	  at	  12°C	  are	  not.	  This	  is	  in	  contrast	  to	  AAC-­‐IIIb,	  where	  it	  is	  structured	  in	  









Figure	  16:	  NMR	  spectra	  of	  ternary	  complexes	  of	  15N	  labeled	  AAC-­‐IIa	  at	  12°C	  	  (red)	  and	  29°C	  
(green):	  (top)	  [AAC-­‐IIa-­‐CoASH]-­‐Tobramycin,	  (bottom)	  [AAC-­‐IIa-­‐	  Tobramycin]-­‐CoASH.	  
	  
	  
When	  considering	  substrate	  promiscuity,	  this	  data	  becomes	  difficult	  to	  interpret.	  
Rationally,	  enzymes	  with	  similar	  substrate	  profile	  should	  show	  similar	  NMR	  spectra	  and	  
dynamic	  behavior;	  however	  such	  is	  not	  the	  case	  when	  it	  comes	  to	  these	  AGMEs.	  In	  the	  absence	  
of	  ligand,	  a	  highly	  promiscuous	  enzyme,	  APH	  (3’)-­‐IIIa	  has	  a	  highly	  overlapped	  1H-­‐15N-­‐HSQC	  
spectrum	  suggesting	  it	  is	  dynamic	  and	  flexible.	  Like	  AAC-­‐IIa,	  upon	  binding	  of	  aminoglycoside	  
tobramycin	  it	  gains	  a	  well-­‐defined	  structure	  and	  unlike	  AAC-­‐IIa	  the	  binding	  of	  co-­‐substrate	  Mg-­‐
ATP	  causes	  minimal	  change	  to	  the	  spectra	  as	  compared	  to	  its	  apo	  form	  [36].	  The	  presence	  of	  
co-­‐substrate	  alters	  the	  conformation	  of	  AAC-­‐IIa,	  as	  the	  spectrum	  becomes	  more	  dispersed	  in	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both	  binary	  and	  ternary	  complexes	  at	  both	  temperatures.	  AAC-­‐IIa	  shows	  dynamic	  behavior	  like	  
the	  APH	  (3’)-­‐IIIa,	  while	  AAC-­‐IIIb	  doesn’t	  but	  substrate	  profiles	  of	  AAC-­‐IIIb	  and	  APH	  (3ʹ′)-­‐IIIa	  are	  
highly	  similar	  and	  significantly	  different	  than	  that	  of	  AAC-­‐IIa.	  Thus,	  these	  results	  indicate	  that	  
flexibility	  alone	  cannot	  account	  for	  the	  substrate	  promiscuity.	   	  
	  
	  
v.	  Structural	  characterization	  of	  AAC-­‐IIa	  	  
	  
To	  determine	  whether	  the	  conformational	  changes	  and	  the	  structural	  changes	  observed	  via	  
NMR	  spectra	  were	  not	  due	  to	  formation	  of	  dimeric	  or	  oligomeric	  species	  of	  the	  enzyme,	  AAC-­‐IIa	  
was	  studied	  using	  Analytical	  ultracentrifugation	  (AUC).	  AUC	  data	  was	  collected	  at	  both	  12°C	  and	  
25	  °C.	  	  
	  The	  structure	  of	  AAC-­‐IIa	  was	  tested	  in	  its	  apo	  form	  with	  varying	  concentrations	  as	  well	  as	  in	  
its	  binary	  and	  ternary	  complex	  states	  by	  AUC.	  Initial	  experiments	  at	  25	  °C	  with	  50	  µM	  AAC-­‐IIa	  in	  
the	  absence	  of	  substrate	  at	  25	  °C	  showed	  a	  sharp	  peak	  (Figure	  14)	  with	  a	  sedimentation	  
coefficient	  (S)	  of	  2.7	  and	  a	  frictional	  ratio	  (f/fo)	  of	  1.33.	  These	  values	  indicate	  a	  molecular	  weight	  
of	  30.9-­‐kDa.	  The	  molecular	  weight	  of	  AAC-­‐IIa	  is	  30.5-­‐kDa,	  so	  this	  data	  suggest	  that	  AAC-­‐IIa	  is	  in	  
a	  monomeric	  state	  in	  its	  apo	  form	  at	  50	  µM	  protein	  concentration.	  	  To	  test	  the	  concentration	  
dependence	  of	  monomer-­‐dimer	  equilibrium,	  if	  any,	  two	  additional	  concentrations,	  30	  µM	  and	  
70	  µM,	  were	  tested	  for	  the	  apo	  AAC-­‐IIa	  at	  25	  °C	  (Figure	  17).	  The	  enzyme	  was	  monomeric	  at	  
both	  concentrations	  with	  S-­‐	  values	  of	  2.7	  and	  molecular	  weight	  of	  30.9-­‐kDa	  Binary	  complexes	  of	  
AAC-­‐IIa	  with	  aminoglycosides	  at	  saturating	  levels	  of	  tobramycin	  and	  co-­‐substrate,	  CoASH,	  at	  50	  
µM	  enzyme	  concentration,	  were	  tested	  at	  25	  °C	  (Figure	  18).	  There	  was	  no	  shift	  in	  the	  S-­‐	  values	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in	  the	  data	  collected	  with	  the	  binary	  complexes	  and	  neither	  a	  shift	  in	  the	  frictional	  ratio	  nor	  a	  
change	  in	  the	  molecular	  weight	  was	  observed.	  Data	  acquired	  with	  two	  ternary	  complexes	  that	  
were	  formed	  with	  reverse	  addition	  of	  tobramycin	  and	  CoASH	  to	  the	  enzyme	  was	  also	  examined	  
(Figure	  19).	  Like	  binary	  complexes,	  ternary	  complexes	  also	  showed	  results	  similar	  to	  apo-­‐AAC-­‐
IIa	  at	  25	  °C.	  These	  observations	  show	  that	  AAC-­‐IIa	  remains	  monomer	  with	  bound	  ligands	  at	  25	  
°C.	  
Interesting	  results	  were	  seen	  from	  studies	  of	  AAC-­‐IIa	  at	  12	  °C.	  	  The	  apo	  AAC-­‐IIa	  at	  12	  °C,	  is	  
found	  to	  be	  dimeric	  with	  an	  f/fo	  of	  1.2	  and	  molecular	  weight	  of	  59.8-­‐kDa.	  However,	  ligand	  
binding	  to	  form	  either	  binary	  or	  ternary	  complexes	  drives	  AAC-­‐IIa	  to	  become	  a	  monomer.	  For	  
the	  binary	  and	  ternary	  complexes	  the	  f/fo	  was	  found	  to	  be	  1.2	  and	  a	  sedimentation	  coefficient	  
2.3	  giving	  a	  molecular	  weight	  of	  30.4-­‐kDa.	  AUC	  studies	  have	  shown	  that,	  AAC-­‐IIIb	  exists	  as	  a	  
dimer	  in	  its	  apo	  state	  as	  well	  as	  in	  various	  binary	  and	  ternary	  complexes	  [40].	  Conversely,	  AAC-­‐
VIa,	  another	  acetyl	  transferase	  with	  the	  most	  limited	  substrate	  profile,	  forms	  a	  dimer	  with	  
increasing	  concentrations	  in	  its	  apo	  form,	  while	  with	  binding	  of	  aminoglycosides	  or	  co-­‐substrate	  
CoASH,	  in	  either	  its	  binary	  or	  ternary	  complexes	  drives	  the	  enzyme	  to	  become	  a	  monomer	  
[Kumar	  and	  Serpersu,	  unpublished].	  	  Literature	  also	  shows	  that	  unlike	  AAC	  (6’)-­‐Ii	  and	  AAC	  (6’)-­‐Iy	  
that	  exist	  as	  dimers,	  AAC	  (6’)-­‐Ib	  and	  AAC	  (6’)-­‐Ib-­‐cr	  are	  monomers	  and	  AAC	  (6’)-­‐Ib11	  exhibits	  a	  
monomer-­‐dimer	  equilibrium	  [51].	  	  
Apo	  AAC-­‐IIa	  at	  12	  °C	  is	  a	  dimer	  and	  at	  25	  °C	  is	  a	  monomer,	  which	  support	  the	  multiple	  
transitions	  observed	  in	  the	  unfolding	  of	  AAC-­‐IIa	  such	  that	  the	  first	  transition	  may	  include	  
conversion	  of	  dimer	  to	  monomer.	  These	  observations	  highlight	  a	  difference	  between	  the	  AAC-­‐
IIIb	  and	  AAC-­‐IIa	  despite	  a	  ~70	  percent	  sequence	  similarity	  between	  them.	  It	  also	  appears	  from	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these	  observations	  that	  perhaps	  dimerization	  could	  be	  the	  cause	  for	  a	  more	  structured	  enzyme.	  
This	  may	  cause	  more	  structural	  control	  on	  the	  active	  site	  to	  increase	  ligand	  promiscuity.	  
	  
	  




Figure	  17:	  AUC	  studies	  of	  apo-­‐AAC-­‐IIa	  at	  varying	  concentrations	  shows	  it’s	  a	  monomer	  
Analytical	  ultracentrifugation	  representative	  raw	  data	  acquired	  by	  analytical	  ultracentrifugation	  









Figure	  18:	  Sedimentation	  plot	  obtained	  from	  AUC	  studies	  of	  binary	  complexes	  of	  AAC-­‐IIa	  with	  








Figure	  19:	  Sedimentation	  plot	  obtained	  from	  AUC	  studies	  of	  ternary	  complexes	  of	  AAC-­‐IIa	  




















vi.Examining	  catalysis	  of	  AAC-­‐IIa	  at	  low	  temperatures	  	  	  
	  
Unfolding	  of	  AAC-­‐IIa	  showed	  the	  presence	  of	  various	  transitions	  indicative	  of	  
conformational	  changes	  at	  low	  temperatures.	  However,	  NMR	  spectra	  revealed	  that,	  at	  
lower	  temperatures	  the	  protein	  is	  still	  highly	  dynamic	  and	  has	  disordered	  regions.	  The	  
catalytic	  activity	  of	  AAC-­‐IIa	  is	  observed	  over	  a	  temperature	  range	  of	  10	  –	  29°C	  to	  see	  if	  the	  
conformational	  changes	  have	  any	  effect	  of	  the	  activity.	  
	  The	  aminoglycoside	  tobramycin	  was	  used	  to	  examine	  the	  temperature	  dependence	  of	  
catalysis	  of	  AAC-­‐IIa.	  	  The	  rates	  increased	  steadily	  between	  temperatures	  10	  °C	  and	  27°C	  and	  
started	  dropping	  from	  temperatures	  29°C	  and	  above	  (Figure	  20).	  There	  is	  a	  steady	  increase	  
in	  activity	  at	  the	  early	  parts	  of	  the	  transitions	  and	  at	  29°C	  AAC-­‐IIa	  starts	  loosing	  activity.	  
29°C	  is	  the	  midpoint	  of	  the	  first	  transition	  observed	  in	  DSC.	  	  This	  suggests	  that	  the	  first	  
transition	  observed	  in	  DSC	  studies	  may	  represent	  melting	  of	  the	  active	  site	  as	  reflected	  in	  
loss	  of	  activity	  above	  this	  temperature.	  
	  These	  data	  obtained	  from	  the	  temperature	  dependence	  study	  (Table	  4)	  were	  used	  to	  
make	  a	  van’t	  Hoff	  plot,	  which	  is	  a	  graph	  of	  natural	  log	  of	  kcat	  as	  a	  function	  of	  inverse	  
temperature	  (Figure	  21).	  The	  slope	  of	  this	  line	  gives	  the	  activation	  enthalpy.	  The	  slope	  being	  
negative	  states	  that	  the	  reaction	  is	  endothermic	  and	  the	  activation	  energy	  was	  calculated	  to	  
be	  12.6	  ±	  0.5	  kcal/mol.	  	  The	  activation	  energy	  is	  the	  minimum	  amount	  of	  energy	  required	  by	  
the	  enzyme	  to	  overcome	  the	  energy	  barrier	  for	  the	  reaction	  to	  proceed	  [52].	  The	  activation	  
energy	  was	  found	  to	  be	  11.6	  kcal/mol	  for	  AAC-­‐IIIb	  with	  kanamycin	  A	  as	  substrate	  	  [Norris	  
and	  Serpersu,	  unpublished].	  Since	  activation	  energies	  for	  AAC-­‐IIa	  and	  AAC-­‐IIIb	  are	  similar,	  it	  
is	  likely	  that	  the	  reaction	  mechanism	  is	  identical	  for	  both	  enzymes.	  Another	  AGME,	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aminoglycoside	  nucleotidyltransferase	  (2”)-­‐Ia	  (ANT	  (2”)-­‐Ia)	  that	  catalyzed	  nucleotidylation	  
of	  aminoglycosides	  has	  significantly	  higher	  activation	  energy	  (19.2	  kcal/mol)	  than	  the	  





Table	  4:	  Kinetic	  parameters	  of	  AAC-­‐IIa	  	  
	  
Temperature	  
(°C)	   1000/T	  (°K)	  
Specific	  activity	  
(μmol/min/mg)	   kcat	  (s-­‐1)	   ln	  kcat	  
10	   3.53	   10.5	  ±	  0.4	   5.7	   1.8	  
12	   3.51	   11.6	  ±	  0.6	   6.4	   1.9	  
15	   3.47	   16.1	  ±	  0.6	   8.8	   2.2	  
17	   3.45	   21.5	  ±	  1.1	   11.8	   2.5	  
19	   3.42	   24.1	  ±	  1.8	   13.2	   2.6	  
21	   3.40	   26.7	  ±	  0.3	   14.6	   2.7	  
23	   3.30	   32.0	  ±	  1.5	   17.5	   2.9	  
25	   3.35	   32.9	  ±	  3.3	   18.0	   2.9	  
27	   3.33	   42.0	  ±	  1.8	   23.0	   3.1	  
























Chapter	  3:	  Conclusion	  and	  Future	  Directions:	  
	  
This	  work	  demonstrates	  that	  AAC-­‐IIa	  undergoes	  conformational	  changes	  at	  low	  
temperatures,	  which	  represents	  a	  novel	  property	  amongst	  the	  AGMEs.	  Noticeably,	  this	  
behavior	  is	  unlike	  that	  characterized	  for	  AAC-­‐IIIb.	  	  The	  overlapped	  NMR	  spectra	  and	  multiple	  
transitions	  observed	  in	  DSC	  studies	  suggest	  that	  the	  enzyme	  AAC-­‐IIa,	  unlike	  AAC-­‐IIIb,	  is	  flexible	  
and	  dynamic.	  Both	  AAC-­‐IIa	  and	  AAC-­‐IIIb	  have	  heat	  capacity	  change	  consistent	  with	  
carbohydrate	  protein	  interactions,	  in	  agreement	  with	  their	  proposed	  mode	  of	  action.	  Like	  most	  
of	  the	  AACs,	  AAC-­‐IIa	  originates	  from	  a	  soil	  bacterium.	  At	  12°C,	  which	  is	  below	  the	  average	  soil	  
temperature	  of	  ~25°C,	  AAC-­‐IIa	  is	  a	  dimer	  in	  its	  apo	  form	  and	  it	  becomes	  monomeric	  upon	  
formation	  of	  a	  complex	  with	  its	  substrate.	  However,	  it	  is	  a	  monomer	  regardless	  of	  substrate	  
binding	  at	  25°C	  while	  AAC-­‐IIIb	  is	  always	  a	  dimer,	  irrespective	  of	  temperature.	  These	  results	  
suggest	  that	  the	  enzymes	  might	  have	  coevolved	  in	  order	  to	  over	  come	  the	  changes	  in	  
temperature.	  
	  
When	  considering	  substrate	  promiscuity,	  these	  data	  become	  difficult	  to	  interpret.	  
Rationally,	  more	  dynamic	  behavior	  the	  enzyme	  portrays,	  the	  more	  promiscuous	  it	  is.	  However,	  
experimental	  evidence	  obtained	  here	  indicates	  that	  it	  is	  not	  the	  case	  for	  these	  classes	  of	  
AGMEs.	  From	  the	  properties	  highlighted	  in	  this	  work,	  dimerization	  may	  be	  a	  key	  difference	  in	  
explaining	  the	  distinct	  substrate	  profiles	  between	  AAC-­‐IIa	  and	  AAC-­‐IIIb.	  Dimerization	  provides	  
these	  enzymes	  with	  more	  structure.	  Structural	  stability,	  in-­‐turn,	  decreases	  the	  enzymes’	  
dynamics	  and	  thereby	  stabilizing	  the	  active	  site	  conformation	  in	  order	  to	  accept	  various	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antibiotics	  including	  neomycins.	  It	  is	  also	  possible	  that	  AAC-­‐IIIb	  has	  evolved	  to	  become	  a	  dimer,	  
allowing	  flexibility	  of	  active	  sites	  aiding	  in	  promiscuity.	  It	  has	  been	  shown	  in	  a	  computational	  
work	  combined	  with	  NMR	  data,	  by	  Norris	  et.al,	  that	  the	  binding	  of	  CoASH	  to	  AAC-­‐IIIb	  increases	  
the	  flexibility	  of	  the	  loop	  region	  of	  the	  antibiotic	  binding	  site	  and	  renders	  the	  motion	  of	  the	  loop	  
residues	  cooperative.	  	  Another	  reason	  for	  the	  differences	  in	  substrate	  profiles	  could	  be	  the	  
difference	  in	  mobility	  of	  the	  loop	  region	  of	  the	  antibiotic	  binding	  site	  that	  is	  common	  in	  both	  
enzymes,	  but	  future	  work	  will	  be	  necessary	  to	  explore	  this	  possibility.	  	  
	  
The	  work	  presented	  here	  provides	  insights	  in	  the	  properties	  of	  AAC-­‐IIa	  but	  more	  
information	  is	  required	  to	  fully	  understand	  these	  systems	  and	  the	  implications	  on	  ligand	  
promiscuity.	  Future	  studies	  could	  include,	  but	  are	  not	  limited	  to,	  the	  role	  of	  solvent	  in	  protein-­‐	  
ligand	  interactions,	  amino-­‐acid	  specific	  labeling	  of	  AAC-­‐IIa	  for	  NMR	  spectral	  assignments,	  X-­‐ray	  
crystal	  structures	  in	  its	  unbound	  and	  various	  ligand	  bound	  forms,	  NMR	  detected	  relaxation	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